[go: up one dir, main page]

WO1996000586A3 - Methods for treating cell proliferative disorders by modulating signal transduction - Google Patents

Methods for treating cell proliferative disorders by modulating signal transduction Download PDF

Info

Publication number
WO1996000586A3
WO1996000586A3 PCT/EP1995/002532 EP9502532W WO9600586A3 WO 1996000586 A3 WO1996000586 A3 WO 1996000586A3 EP 9502532 W EP9502532 W EP 9502532W WO 9600586 A3 WO9600586 A3 WO 9600586A3
Authority
WO
WIPO (PCT)
Prior art keywords
signal transduction
receptor
proliferative disorders
methods
cell proliferative
Prior art date
Application number
PCT/EP1995/002532
Other languages
French (fr)
Other versions
WO1996000586A9 (en
WO1996000586A2 (en
Inventor
Gabriela A Fischer
Axel Ullrich
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Priority to AU29789/95A priority Critical patent/AU2978995A/en
Publication of WO1996000586A2 publication Critical patent/WO1996000586A2/en
Publication of WO1996000586A3 publication Critical patent/WO1996000586A3/en
Publication of WO1996000586A9 publication Critical patent/WO1996000586A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of proteins, peptides and organic molecules capable of modulating inositol 1,4,5-triphosphate (IP3) receptor signal transduction in order to inhibit or reverse inappropriate growth of cells associated with abnormalities of signal transduction associated with tyrosine kinases. The present invention also relates to the use of IP3 receptor mutants in the treatment of proliferative disorders associated with abnormalities of signal transduction associated with tyrosine kinases, including cancer. The present invention also relates to the use of IP3 receptor and genetically engineered host cells that express the IP3 receptor to evaluate and screen for substances and compounds that modulate IP3 receptor activities.
PCT/EP1995/002532 1994-06-30 1995-06-29 Methods for treating cell proliferative disorders by modulating signal transduction WO1996000586A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU29789/95A AU2978995A (en) 1994-06-30 1995-06-29 Methods for treating cell proliferative disorders by modulating signal transduction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26839094A 1994-06-30 1994-06-30
US08/268,390 1994-06-30

Publications (3)

Publication Number Publication Date
WO1996000586A2 WO1996000586A2 (en) 1996-01-11
WO1996000586A3 true WO1996000586A3 (en) 1996-02-15
WO1996000586A9 WO1996000586A9 (en) 1996-02-29

Family

ID=23022786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002532 WO1996000586A2 (en) 1994-06-30 1995-06-29 Methods for treating cell proliferative disorders by modulating signal transduction

Country Status (2)

Country Link
AU (1) AU2978995A (en)
WO (1) WO1996000586A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465211B1 (en) * 1998-08-27 2002-10-15 Riken Nucleic acids, vectors and transformed cells for making and using high affinity IP-3 binding polypeptides
US7091173B1 (en) * 2001-10-30 2006-08-15 Myriad Genetics, Inc. FAP48-interacting proteins and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520372A1 (en) * 1991-06-26 1992-12-30 Hoechst Aktiengesellschaft Inositol phosphate analogues as calcium-antagonistic substances
WO1994007507A1 (en) * 1992-09-28 1994-04-14 Merrell Dow Pharmaceuticals Inc. Method for antagonizing inositol 1,4,5-triphosphate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520372A1 (en) * 1991-06-26 1992-12-30 Hoechst Aktiengesellschaft Inositol phosphate analogues as calcium-antagonistic substances
WO1994007507A1 (en) * 1992-09-28 1994-04-14 Merrell Dow Pharmaceuticals Inc. Method for antagonizing inositol 1,4,5-triphosphate

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A. KOZIKOWSKI ET AL.: "The novel Ins(1,4,5)P3 analogue 3-amino-3-deoxy-Ins(1,4,5)P3: a pH-dependent Ins(1,4,5)P3 receptor partial agonist in SH-SY5Y neuroblastoma cells.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 6, 18 March 1994 (1994-03-18), WASHINGTON, DC, USA, pages 868 - 872 *
A. MIYAWAKI ET AL.: "Structure-function relationships of the mouse inositol 1,4,5-triphosphate receptor.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 88, no. 11, 1 June 1991 (1991-06-01), WASHINGTON, DC, USA, pages 4911 - 4915 *
E. CLEMENTI ET AL.: "Effects of mutated IP-3 receptors on signal transduction and EGF-dependent cell growth.", CELL BIOLOGY INTERNATIONAL REPORTS, vol. 18, no. 5, LONDON, GB, pages 381 *
G. FISCHER ET AL.: "Stable expression of truncated inositol 1,4,5-triphosphate receptor subunits in 3T3 fibroblasts.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 30, 29 July 1994 (1994-07-29), BALTIMORE, MD, USA, pages 19216 - 19224 *
G. MIGNERY ET AL.: "Structure and expression of the rat inositol 1,4,5-triphosphate receptor.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 21, 25 July 1990 (1990-07-25), BALTIMORE, MD, USA, pages 12679 - 12685 *
G. MIGNERY ET AL.: "The ligand binding site and transduction mechanism in the inositol-1,4,5-triphosphate receptor.", THE EMBO JOURNAL, vol. 9, no. 12, OXFORD, GB, pages 3893 - 3898 *
O. BLONDEL ET AL.: "Sequence and functional characterization of a third inositol triphosphate receptor subtype, IP3R-3, expressed in pancreatic islets, kidney, gastrointestinal tract, and other tissues.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 15, 25 May 1993 (1993-05-25), BALTIMORE, MD, USA, pages 11356 - 11363 *

Also Published As

Publication number Publication date
AU2978995A (en) 1996-01-25
WO1996000586A2 (en) 1996-01-11

Similar Documents

Publication Publication Date Title
AU8143894A (en) Mck-10 (mammary carcinoma kinase 10), a receptor tyrosine kinase
CA2192797A1 (en) Indolinone compounds for the treatment of disease
HU9602975D0 (en) Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression, process of making thereof
HUT75825A (en) Protocadherin proteins and their uses
EP0923293A4 (en) Treatment of diarrhea
AU4833897A (en) Glial mitogenic factors, their preparation and use
CA2137878A1 (en) Photosensor with multiple light sources
NO985022L (en) High absorption / low reflectance filter with a pattern layer
PL329922A1 (en) Quinoline carboxamides as inhibitors of the tumour necrosis factor and of phosphodiesterase
WO1994024160A3 (en) Erythropoietin muteins with enhanced activity
DE69941701D1 (en) MUTANTS OF FLT3-L AND ITS USES
NO960309L (en) Agonists and antagonists of human interleukin-10
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
ZA200107283B (en) Vascular adhesion molecules and modulation of their function.
ATE433461T1 (en) RANA PIPIEN'S PROTEINS AND THEIR USE IN THE TREATMENT OF TUMORS
CA2117581A1 (en) Protocadherin, their antibodies and uses
EP2011873A3 (en) Tumor necrosis factor receptor-associated factors
WO1996000586A3 (en) Methods for treating cell proliferative disorders by modulating signal transduction
AU5301499A (en) Method for screening candidate compounds for drug against tumor
WO2002005843A3 (en) Human rrp sequences and methods of use
EP1331265A3 (en) density enhanced protein tyrosine phosphatases
AU4779599A (en) Methods of inhibiting (helicobacter pylori)
WO1995007708A3 (en) Therapeutic use of the retinoblastoma susceptibility gene product
DE69319346D1 (en) TREATMENT OF TUMORS WITH NEUTROPHIC FACTORS AND INHIBITORS OF CELL PROLIFERATION
WO2004016761A3 (en) Gene therapy for critical limb ischemia with wild type or mutant enos

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT KE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 7/21-21/21,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA